Drug Treatment

/Drug Treatment

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2018-10-30T09:34:18+00:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Webcast Provides Perspective on Generic Imatinib

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time [...]

By |2018-10-30T09:55:00+00:00April 8th, 2016|Generics, GIST Education, Newsletter, Webcast|

Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]

By |2018-10-30T09:55:33+00:00March 15th, 2016|Drug Treatment, News, Survival Strategies|

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. LRG Research Program to [...]

By |2018-10-30T11:12:50+00:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09+00:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Immunotherapy: Game Changing Cancer Treatments

Two recent articles summarize the promise that immunotherapy provides for the future of cancer treatment. Immunotherapy refers to treatments that aid your own immune system in fighting cancer cells. The first, from U.S. News [...]

By |2018-11-05T14:35:28+00:00October 15th, 2015|Drug Treatment, News, Research|

Need for Extended Adjuvant Treatment to Prevent Recurrence in GIST May Be Underestimated

A recent study in JAMA Oncology found that patients who undergo primary GIST resection might not receive the optimal recommended duration of adjuvant therapy, which can impact their recurrence-free survival (RFS).The study was conducted by [...]

Recent Posts

Upcoming Events

  1. GDOL Los Angeles 2019

    February 16, 2019 @ 8:00 AM - 5:00 PM